Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Latikafusp · AMG 256

Fusion protein · Inhibitor of Programmed cell death protein 1 (PDCD1) and Interleukin-21 receptor (IL21R) · developed by AMGEN

Phase 1 Most advanced trial (none active)
AMGN Developer

What is Latikafusp?

Latikafusp (AMG 256) is a fusion of an antibody against PD-1 with a mutein of interleukin-21. The antibody binds PD-1 on T-cells to inhibit its checkpoint signaling, while the IL-21 moiety binds the IL-21 receptor and activates cytokine signaling in PD-1-expressing cells. It is studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AMG 256
Drug type
Fusion protein
Targets
Programmed cell death protein 1 (PDCD1), Interleukin-21 receptor (IL21R)
Mechanism
Inhibitor of Programmed cell death protein 1 (PDCD1) and Interleukin-21 receptor (IL21R)
Pathways
PD-1 signaling, IL-21 cytokine signaling, T-cell activation
Therapy area
Oncology
Developer
AMGEN (AMGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
F188ZI78F7

Conditions studied

Advanced Solid Tumors

Other drugs acting on PDCD1 / IL21R

More from AMGEN

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Latikafusp

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.